ALPHAMAB ONCOLO.DL-000002 Cash Flow Quality Index
ALPHAMAB ONCOLO.DL-000002 cash flow quality index. ALPHAMAB ONCOLO.DL-000002 (3NK) has a Cash Flow Quality Index of 1.28x as of December 2024. Operating cash flow of €212.34 Million exceeds net income of €166.34 Million, indicating high earnings quality where cash backs reported profits. See how financially flexible is ALPHAMAB ONCOLO.DL-000002 to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of ALPHAMAB ONCOLO.DL-000002 (2024–2024)
Cash flow quality index of ALPHAMAB ONCOLO.DL-000002 from 2024 to 2024. Historical Cash Flow Quality Index for ALPHAMAB ONCOLO.DL-000002 across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 3NK operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
ALPHAMAB ONCOLO.DL-000002 Cash Flow Quality Index by Year (2024–2024)
ALPHAMAB ONCOLO.DL-000002 cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for ALPHAMAB ONCOLO.DL-000002. For the full cash flow conversion analysis, see 3NK operating cash flow.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.28x | €212.34 Million | €166.34 Million | — |